Most Popular
-
1
1 in 3 Koreans live alone, family types becoming diverse
-
2
Korea, Japan finance chiefs vow to tame rampant FX market volatility
-
3
K-pop singer lost consciousness after being hit by foul ball, cancels show
-
4
K-pop group's manager dismissed for setting up spycam in theater dressing room
-
5
Contentious grain bill put directly to plenary meeting for vote
-
6
Korean Muslim YouTuber's plan to build mosque in Incheon goes viral
-
7
Why is Apple Pay struggling to get purchase in Korea?
-
8
Yoon's office denies considering liberal figures for key posts
-
9
Trilateral talks acknowledge ‘serious’ slumps of won, yen
-
10
[Today’s K-pop] BTS pop-up event to come to Seoul
![[Today’s K-pop] BTS pop-up event to come to Seoul](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/17/20240417050734_0.jpg&u=)
![[Today’s K-pop] BTS pop-up event to come to Seoul](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/17/20240417050734_0.jpg&u=)
Boryung acquires rights in Korea for Eli Lilly’s Gemzar
By Lim Jeong-yeoPublished : May 12, 2020 - 10:39
Boryung Pharmaceutical has acquired all rights to Eli Lilly’s anti-cancer drug Gemzar in South Korea, the company said Monday.
“We have strengthened our anti-cancer treatment portfolio through Gemzar. With continuing investments, we will grow the anti-cancer department as one of Boryung’s representative business areas,” said CEO Ahn Jae-hyun.
Gemzar (gemcitabine) is a nucleoside metabolic inhibitor indicated for pancreatic cancer and, in combination with other drugs, indicated for advanced ovarian cancer, metastatic breast cancer and non-small cell lung cancer.
According to market researcher IQVIA, Gemzar logged 14.2 billion won ($11.6 million) in revenue in Korea last year.
In the domestic anti-cancer treatment market, Boryung also has rights to distribute drugs such as Oxalitin (oxaliplatin) and Genexol (paclitaxel).
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
“We have strengthened our anti-cancer treatment portfolio through Gemzar. With continuing investments, we will grow the anti-cancer department as one of Boryung’s representative business areas,” said CEO Ahn Jae-hyun.
Gemzar (gemcitabine) is a nucleoside metabolic inhibitor indicated for pancreatic cancer and, in combination with other drugs, indicated for advanced ovarian cancer, metastatic breast cancer and non-small cell lung cancer.
According to market researcher IQVIA, Gemzar logged 14.2 billion won ($11.6 million) in revenue in Korea last year.
In the domestic anti-cancer treatment market, Boryung also has rights to distribute drugs such as Oxalitin (oxaliplatin) and Genexol (paclitaxel).
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240419100350)
